GlassScriptPhysician profile
Amy Goldstein
NPI 1285662908
$5,958.86
in general payments reported to CMS, 2019-2025
29 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $161 · 2022: $805 · 2023: $1,348 · 2024: $1,453 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.08 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $987.68 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $810.31 | 2019-2025 | |
| Genzyme Corporation | $557.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $424.21 | 2022-2025 | Sotyktu |
| Pfizer INC. | $362.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $276.84 | 2019-2025 | Dupixent |
| Incyte Corporation | $257.51 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $244.25 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $223.48 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $222.58 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Merz North America, INC. | $214.84 | 2023 | Xeomin |
| Galderma Laboratories, L.P. | $143.11 | 2019-2025 | Dysport, Aklief, Nemluvio |
| Allergan, INC. | $138.95 | 2019 | |
| Ucb, INC. | $118.14 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.63 | 2023 | Cyltezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $103.47 | 2023-2025 | Zoryve |
| Biofrontera INC. | $100.95 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $93.61 | 2025 | Ebglyss |
| Lnhc, INC | $87.25 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $83.32 | 2023-2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.29 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Organon LLC | $72.04 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $68.37 | 2019-2025 | |
| Dermavant Sciences, INC. | $66.73 | 2022-2024 | Vtama |
| Journey Medical Corporation | $37.39 | 2022-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $24.75 | 2025 | Valchlor |
| Epi Health, LLC | $21.47 | 2019 | |
| Sebela Pharmaceuticals INC. | $17.65 | 2019 | |
| Aclaris Therapeutics, INC. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.